HOME | DD
Market364 — RNA-Analysis-Transcriptomics-Market
#analysis #growth #market #rna #scope #share #size #transcriptomics
Published: 2023-07-19 09:00:59 +0000 UTC; Views: 304; Favourites: 3; Downloads: 0
Redirect to original
Description
The global transcriptomics market is experiencing significant growth, fueled by the increasing demand for personalized medicine in cancer treatment and the advancements in RNA analysis technologies. Transcriptomics, the study of the entire RNA transcript present in a cell or cell population, plays a crucial role in investigating gene expressions and understanding the journey of DNA to protein through mRNA, known as gene expression.
For More Industry Insight Read : www.fairfieldmarketresearch.co…
The field of transcriptomics emerged in the 1990s with promising approaches to study gene expression, and since then, it has witnessed remarkable growth due to various factors. The expansion of the RNA analysis transcriptomics market is driven by the escalating need for pharmaceutical and biotechnology research and development (R&D) investments, government funding for omics research, and the growing utilization of RNA sequencing in the transcriptomics industry.
One of the primary drivers of market growth is the increasing demand for personalized medicine in cancer treatment. Personalized medicine has revolutionized clinical practice, transforming how diseases are discovered, categorized, and treated. In the United States alone, the availability of personalized medicines has grown from 36 drugs in 2010 to 286 drugs in 2020, indicating a significant market expansion. The rising prevalence of cancer worldwide, with an estimated 18.1 million cancer cases in 2020, further boosts the demand for personalized medicine and contributes to the growth of the RNA analysis transcriptomics market.
The reagents segment is dominating the RNA analysis transcriptomics market, primarily due to the high demand for high-quality reagents and kits in transcriptome research. These reagents and kits offer exceptional binding properties, ensuring reliable and reproducible sequencing results at a low cost. The pharmaceutical sector's increasing R&D efforts, augmented government spending on life science research, and technological advancements drive the growth of this segment.
North America holds the prime position in the RNA analysis transcriptomics market, accounting for the highest revenue share. The region benefits from the development of structure-based drug designs, substantial investments in genomics and proteomics research by academic and government institutions, high life science research funding, and the adoption of advanced technologies. Additionally, the presence of numerous global players and ongoing research and development activities in the private sector further contribute to North America's dominance in the market.
Asia Pacific is expected to witness significant growth during the forecast period, driven by the region's growing number of pharmaceutical and biotechnology companies. Increased demand for transcriptomics technologies, investments in R&D, and drug development efforts further propel the market growth in this region. Governments and non-governmental organizations in countries like Japan strongly support biotechnology research and provide funding, encouraging researchers to explore the field of transcriptomics extensively.
Key players in the global RNA analysis transcriptomics market include Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., Merck KGaA, QIAGEN N.V., Illumina, Inc., Danaher Corporation, Fluidigm Corporation, F. Hoffmann-La Roche Ltd., Sequentia Biotech SL, Eurofins Scientific, GenXPro GmbH, Acobiom, bioMérieux SA, CD Genomics, Lexogen GmbH, Promega Corporation, Takara Holdings, Inc., Cenix BioScience GmbH, and LC Sciences LLC.
To stay competitive, market participants are continuously launching new products and forming strategic alliances, collaborations, and partnership agreements. For instance, in February 2021, Parse Biosciences introduced the Single Cell Whole Transcriptome Kit, expanding access to North American researchers. Similarly, Agilent Technologies Inc. announced the availability of the SureSelect XT HS2 RNA Reagent Kit in September 2020, offering streamlined and consolidated workflow solutions.
The global transcriptomics market is poised for substantial growth as personalized medicine gains traction and RNA analysis technologies continue to advance. With increasing investments in R&D, expanding pharmaceutical and biotechnology sectors, and a focus on innovative solutions, the market is expected to thrive in the coming years.
